COMMUNIQUÉS West-GlobeNewswire

Orion Group Financial Statement Release January–December 2025
12/02/2026
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October– [...]
Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026
12/02/2026
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 [...]
Notice to the Annual General Meeting of Orion Corporation
12/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 12 FEBRUARY 2026 at 12:05 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of [...]
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
12/02/2026
Third party commercial assessment shows larger than expected potential total addressable market for IGALMI ® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary [...]
Kane Biotech Restarts Commercial Activities and Strengthens North American Management
12/02/2026
Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or [...]
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
12/02/2026
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving [...]
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
12/02/2026
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE [...]
EDAP Announces Appointment of David Horn to Board of Directors
12/02/2026
EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound technology, today [...]
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
12/02/2026
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has [...]
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG
12/02/2026
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG Boston, MA, USA and Oxford, UK – 12 February 2026 , Vitaccess, a leader in generating [...]
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
12/02/2026
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
12/02/2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its [...]
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
12/02/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the [...]
Nicox confirme son éligibilité au PEA-PME
12/02/2026
Communiqué de presse Nicox confirme son éligibilité au PEA-PME 12 février 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
12/02/2026
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul [...]
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi
12/02/2026
Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul [...]
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
12/02/2026
Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
12/02/2026
Oslo, Norway, 12 th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin [...]

Pages